{
    "nct_id": "NCT04613492",
    "official_title": "An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination With Durvalumab in Participants With Select Advanced/Metastatic Solid Tumors",
    "inclusion_criteria": "1. Participant must be at least 18 years old at signing of informed consent.\n2. Body weight > 35 kg at screening\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 101 Years",
    "exclusion_criteria": "1 Primary central nervous system (CNS) disease is excluded, as well as untreated or uncontrolled metastatic CNS involvement, leptomeningeal disease, or cord compression.\n\nNOTE: CNS disease that has been treated and stable/controlled for at least 3 months is permitted. Participants with CNS disease controlled via systemic steroids are not permitted.",
    "miscellaneous_criteria": ""
}